Complement Therapeutics, a Munich, Germany-based preclinical stage biotechnology company, raised €72M in Series A funding.
The round was led by Gimv, and Forbion with participation from BioGeneration Ventures (BGV), Panakès Partners, Cambridge Innovation Capital (CIC), Hadean Ventures and Seroba Life Sciences. Alongside the financing, Michaël Vlemmix (Gimv), Rob Woodman (Panakès), Anne Horgan (CIC) and Roger Franklin(Hadean Ventures) will join the board as new members.
Led by CEO Dr Rafiq Hasan, Complement Therapeutics is an early-stage biotechnology company focused on the research and development of novel therapeutics for complement- mediated diseases. The company, a spinout from the University of Manchester, is based on the research of targets within the complement cascade. Its investigational product (CTx001), a highly innovative AAV gene therapy for the treatment of Geograpic Atrophy (GA) secondary to dry age-related macular degeneration (dry-AMD), is being evaluated as a potential gene therapy for GA, a leading cause of blindness. The company is also developing a quantification methodology, the Complement Precision Medicine (CPM) platform, to enable the quantification of over 30 complement cascade proteins enabling diagnosis and monitoring of disease.
The company intends to use the funds to continue the development and complete a Phase Ib clinical proof of concept of its lead product CTx001, to grow its laboratory-based activities in Stevenage (UK), evaluate its pipeline assets for non-ocular indications as well as further develop the novel Complement Precision Medicine (CPM) platform.
FinSMEs
17/04/2023